Short Bowel Syndrome - Pipeline Review, H1 2017

Date: June 13, 2017
Pages: 54
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S7F55ECFCBAEN
Leaflet:

Download PDF Leaflet

Short Bowel Syndrome - Pipeline Review, H1 2017
Short Bowel Syndrome - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 1, 2 and 6 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome - Overview
Short Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Short Bowel Syndrome - Companies Involved in Therapeutics Development
Ardelyx Inc
Hanmi Pharmaceuticals Co Ltd
Naia Ltd
Nutrinia Ltd
OxThera AB
Sancilio & Company Inc
Shire Plc
Tasly Pharmaceutical Group Co Ltd
Zealand Pharma AS
Short Bowel Syndrome - Drug Profiles
exenatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15910 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRA-9620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-98940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
Oct 20, 2015: Naia Rare Diseases a subsidiary of Naia, Receives Orphan Drug Designation From U.S. FDA For NB1001 For The Treatment Of Short Bowel Syndrome
Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Short Bowel Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2017
Short Bowel Syndrome - Pipeline by OxThera AB, H1 2017
Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2017
Short Bowel Syndrome - Pipeline by Shire Plc, H1 2017
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2017
Short Bowel Syndrome - Dormant Projects, H1 2017
Short Bowel Syndrome - Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Ardelyx Inc
Hanmi Pharmaceuticals Co Ltd
Naia Ltd
Nutrinia Ltd
OxThera AB
Sancilio & Company Inc
Shire Plc
Tasly Pharmaceutical Group Co Ltd
Zealand Pharma AS
Skip to top


Ask Your Question

Short Bowel Syndrome - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: